α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo

Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology

Dopamine Stabilization and Neurodegeneration with Alpha Synuclein Oligomers

IJMS, Free Full-Text

Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome

Full article: Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease

Frontiers The Role of Lipids in the Initiation of α-Synuclein Misfolding

Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson's Disease

Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation: Molecular Therapy - Nucleic Acids

Salidroside protects SH‑SY5Y from pathogenic α‑synuclein by promoting cell autophagy via mediation of mTOR/p70S6K signaling

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome

Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease

Alpha Synuclein in Parkinson's Disease Diagnostics

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease